Mounjaro 7.5mg weight loss results: what the evidence shows

What kind of weight loss do people typically see at the 7.5mg stage?

It helps to think of Mounjaro's results as cumulative rather than dose-specific. The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed nearly 2,540 adults with obesity over 72 weeks. Participants taking tirzepatide at the highest tested doses lost an average of around 20–21% of body weight. That figure represents the full arc of treatment (from the 2.5mg starter all the way through to 15mg maintenance) not a snapshot at 7.5mg alone.

By the time most people reach 7.5mg, around 12 weeks in, cumulative weight loss is typically somewhere between 5–10% of starting body weight, though individual variation is wide. Appetite suppression usually strengthens with each upward step. Portion sizes that felt normal before treatment often feel uncomfortably large by the time 7.5mg is reached, a practical signal that the medicine is working as intended.

Weight loss at this dose also depends heavily on lifestyle factors alongside treatment. The licence specifically covers Mounjaro as an adjunct to a reduced-calorie diet and increased physical activity, not a standalone fix. Our full Mounjaro overview sets out the evidence base in detail for anyone who wants the broader picture before deciding whether to start.

Why does Mounjaro use a step-by-step titration rather than starting at the full dose?

The titration schedule exists primarily to protect tolerability. Tirzepatide slows how quickly the stomach empties, helpful for appetite control, but a significant trigger for nausea and digestive discomfort if the dose jumps too quickly. Starting at 2.5mg and increasing in roughly four-week steps gives the gut time to adapt at each level, and our guide to coming off the 2.5mg starting dose explains what that transition looks like if you ever need to step back down. You can read more about the early experience in our guide to the 2.5mg starting dose.

The 7.5mg pen is the point where many people notice a clearer appetite shift than at 5mg. That is expected: GIP and GLP-1 receptor activation intensifies with concentration, so satiety signals strengthen as the dose rises. Some people find this stage brings the most noticeable change in food behaviour, eating less without consciously trying to.

Clinically, 7.5mg also matters because it sits in the middle of the range. A prescriber reviewing your progress here can judge whether you are tolerating the medicine well enough to continue titrating, or whether staying at 7.5mg for longer makes more sense. Suitability at each step is reassessed, not assumed. If you are curious about how progression from the previous step compares, the 5mg weight loss page covers that transition in detail.

What side effects tend to appear or continue at 7.5mg?

The side-effect profile at 7.5mg mirrors what is described across the Mounjaro programme: nausea is the most commonly reported complaint, followed by loose stools or constipation, indigestion, fatigue and reduced appetite. These effects are not new at 7.5mg, they tend to follow dose increases and then ease, usually within a week or two, as the body adjusts.

A few things are worth knowing. Staying well hydrated matters more than many people expect, especially if appetite suppression means eating much less than before. Eating slowly and in smaller portions helps reduce nausea. The pen itself should be stored in the fridge, many people keep it in the door, which works well as long as the compartment stays consistently cool.

Rare but serious signs (severe stomach pain that radiates to the back, persistent vomiting, or signs of a hypersensitivity reaction) warrant prompt medical attention. The NHS tirzepatide medicines page lists the full side-effect profile and explains which symptoms need urgent review. Side effects can also be reported directly to the MHRA at yellowcard.mhra.gov.uk.

Does staying at 7.5mg make sense, or should you keep titrating?

That depends on your individual response and tolerability, and it is exactly the kind of question a prescriber works through with you. NICE's guidance on tirzepatide recommends reviewing progress at six months: if weight loss falls below 5% at the highest tolerated dose, the clinical case for continuing is reconsidered. That threshold applies across the titration, not just at one step.

Some people find 7.5mg delivers strong results with good tolerability and feel no urge to increase. Others move steadily toward 10mg, 12.5mg and ultimately 15mg, where the trial data show the greatest average reductions. Neither path is automatically right. If the question of what happens further along the schedule interests you, the 7.5mg weight loss overview and our treatment pricing page cover ongoing costs and what each step involves.

The decision to titrate, hold or adjust is one our prescribers review before every repeat, no automatic renewals, no assumption that more is always better. If you are weighing whether this is the right point to start treatment, or wondering what your own results might look like, speaking to a prescriber is the clearest next step. Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.